Notably, the combination of nicotinamide riboside and pterostilbene (EH301), which are proposed to be activators of sirtuin 1, is presently in phase III clinical trial (NO‐ALS). This evidence concerns the gene SIRT1 and amyotrophic lateral sclerosis.